Research

Future & Ongoing

Registry

In 2013 we launched an ongoing cancer registry through an Institutional Review Board approved study at M. D. Anderson Cancer Center. The purpose of the research is to obtain information about diagnosis, stage, treatment and survival of women with this disease.

Clinical Trial

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

This phase II trial studies the effect of AK104 (cadonilimab) in treating high grade neuroendocrine carcinoma of the cervix. AK104 (cadonilimab) is a new type of immunotherapy drug. Immunotherapy with monoclonal antibodies, such as AK104 (cadonilimab), may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Prior studies with similar immunotherapy drugs in patients with high grade neuroendocrine carcinoma at multiple sites, including cervical, have shown disease regression in some of the patients. All patients enrolled on the trial will get AK104 (cadonilimab) and no patients will get placebo. This study has 18 spots for women with any type of high grade neuroendocrine cervical cancer.

E-mail our team for more information about the trial: nectur@mdanderson.org

https://clinicaltrials.gov/ct2/show/NCT05063916?term=ak104&draw=3&rank=12

Research Papers

The Texas Cocktail: Combination Therapy with Topotecan, Paclitaxel, and Bevacizumab for Recurrent Small Cell Neuroendocrine Carcinoma of the Cervix (2017)

Download this article as a PDF

MD Anderson Recommendation Guidelines (2019)

Download this article as a PDF

This manuscript received the International Gynecologic Cancer Society (IGCS) 2020 award for Most Downloaded Paper.

Early-Stage High-Grade Neuroendocrine Carcinoma (2020)

Download this article as a PDF

Society of Gynecologic Oncology (SGO) Recommendation Guideline 2021

Download this article as a PDF

Single Agent Pembrolizumab for Recurrent Small Cell Neuroendocrine Carcinoma of the Cervix (2020)

Download this article as a PDF

Comparative Genomics of High-Grade Neuroendocrine Carcinoma of the Cervix (2020)

Download this article as a PDF

Genomic Landscape of High-Grade Neuroendocrine Cervical Cancer (2020)

Download this article as a PDF

Mutations in Cervical Small Cell Neuroendocrine Tumors (2016)

Download this article as a PDF

Case Study 2021

Download this article as a PDF

HPV and neuroendocrine carcinoma of the cervix

Download this article as a PDF

Next-generation sequencing of cancer-related genes in small cell carcinoma

Download this article as a PDF

PARP and PDL-1 as potential therapeutic targets for neuroendocrine carcinoma of the cervix

Download this article as a PDF

Interviews

IJGC Podcast

Dr. Michael Frumovitz is interviewed on the IJGC podcast in 2019.

View on Apple Podcasts

IJGC Journal April 2021 Discussion

USGO 2021 IJGC Presentation

Scroll to Top